Synthesis, Biological Evaluation, and Molecular Docking of Arylpyridines as Antiproliferative Agent Targeting Tubulin. 2020

JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
Innovation Program of Drug Research on Neurological and Metabolic Diseases, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.

Mimicking different pharmacophoric units into one scaffold is a promising structural modification tool to design new drugs with enhanced biological properties. To continue our research on the tubulin inhibitors, the synthesis and biological evaluation of arylpyridine derivatives (9-29) are described herein. Among these compounds, 6-arylpyridines (13-23) bearing benzo[d]imidazole side chains at the 2-position of pyridine ring displayed selective antiproliferative activities against HT-29 cells. More interestingly, 2-trimethoxyphenylpyridines 25, 27, and 29 bearing benzo[d]imidazole and benzo[d]oxazole side chains displayed more broad-spectrum antitumor activities against all tested cancer cell lines. 29 bearing a 6-methoxybenzo[d]oxazole group exhibited comparable activities against A549 and U251 cells to combretastatin A-4 (CA-4) and lower cytotoxicities than CA-4 and 5-Fu. Further investigations revealed 29 displays strong tubulin polymerization inhibitory activity (IC50 = 2.1 μM) and effectively binds at the colchicine binding site and arrests the cell cycle of A549 in the G2/M phase by disrupting the microtubules network.

UI MeSH Term Description Entries

Related Publications

JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
January 2018, Anti-cancer agents in medicinal chemistry,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
January 2019, European journal of medicinal chemistry,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
August 2018, Bioorganic chemistry,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
August 2023, Journal of molecular structure,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
January 2018, Current drug discovery technologies,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
May 2018, RSC advances,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
May 2014, Molecules (Basel, Switzerland),
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
April 2022, Drug development research,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
March 2020, Pakistan journal of pharmaceutical sciences,
JiaPeng He, and Mao Zhang, and Lv Tang, and Jie Liu, and JiaHong Zhong, and Wenya Wang, and Jiang-Ping Xu, and Hai-Tao Wang, and Xiao-Fang Li, and Zhong-Zhen Zhou
January 2021, Medicinal chemistry (Shariqah (United Arab Emirates)),
Copied contents to your clipboard!